STIFEL 2026: Korsana Biosciences is using a proprietary brain shuttle and a beta amyloid targeting therapy and aims to take Alzheimer's treatment to the next level
From BiotechTV - News · · 9 min
This plays from the publisher's own server. We do not host a copy.
Not rated yet
Description
President and CEO Jonathan Violin compares and contrasts his product with other brain shuttles and discusses the road ahead. They will present preclinical data at CTAD next week and the clinical program will ramp up and have initial data in 2027. Korsana recently went public through a reverse merger.